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INTRODUCTION
The attempted reduction of colorectal cancer (CRC) mortality is
an issue of great importance. It is the second most frequent cancer
in men and women in Europe and North America (Parkin et al,
1997). Despite advances in diagnostic techniques and treatment,
the 5-year survival rate remains poor (Berrino et al, 1995). Three
randomized studies have indicated that faecal occult blood testing
(FOBT) followed, in the event of a positive test, by a colonoscopy
to detect the source of bleeding can reduce CRC mortality
(Kronborg et al, 1996; Hardcastle et al, 1996; Mandel et al, 1993).
The results of one of these studies, conducted in volunteers, with a
high positivity rate of rehydrated FOBT, are not applicable to a
general population (Mandel et al, 1993). In particular, it is not
possible to perform a colonoscopy on as much as nearly 10% of
the population at each screening round. The two population-
based studies from Denmark and England indicate that biennial
screening with FOBT can reduce CRC mortality by 15—18%. It is
not known whether the results of these studies can be extrapolated
to other countries (such as France) where the prognosis of CRC in
the general population is better than in Denmark or England
(Berrino et al, 1995). In this situation, the reduction in CRC
mortality due to FOBT might be lower and a population-based
controlled study of the question is under way in Burgundy (Tazi 
et al, 1997). The final results will be available within 2 years. In
order to provide an interim evaluation of efficacy of the
programme, we conducted a case—control study within the
enrolled arm of the population study, comparing participants with
non-participants to evaluate the effect of screening on mortality
from colorectal cancer, taking into consideration the relationship




The design of the study has been reported previously (Tazi et al,
1997). Briefly, faecal occult blood screening using the Hemoccult
II test was offered to all the residents of 12 well-defined adminis-
trative areas of Burgundy (France) who were born between 1914
and 1943. The enrolled population was 45 642. The first screening
campaign began in 1988 and, for part of the study population, in
1989. It was repeated in 1990, 1992 and 1994. No other method of
screening for CRC was offered to this population. The screening
test was provided free of charge by primary care physicians over a
4-month period, then posted to persons who had not consulted a
general practitioner during this period, with a reminder letter after
a month to non-responders. A colonoscopy was offered if the test
was positive. The entire enrolled population was invited to partici-
pate in each screening campaign.
Identification of cases
Eligible cases were those who were residents of areas covered by
the screening programme, with a colorectal adenocarcinoma diag-
nosed between 1988 or 1989 (according to the year of inclusion
into the programme) and 1995, who subsequently died before
December 1996. Cases were identified either from files of the
population-based cancer registry covering the study population, or
through the data collection system of the screening programme.
Information on method of diagnosis, subsite, histological type,
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treatment and stage at diagnosis was verified by reviewing all
available medical records. Details of death were ascertained from
death certificates, cancer registry information, local registers of
births, marriages and deaths and from general practitioners. There
was a total of 214 potentially eligible cases. Death was attributed
to colorectal cancer if advanced or metastatic colorectal cancer
was present at the time of death or if the case died in the post-oper-
ative phase. In the few instances in which the cause of death could
not be easily determined, it was decided by an expert physician
and a pathologist external to the study. Classification of the cause
of death was carried out blind to screening history. The 36 ineli-
gible subjects included nine whose death was due to another
cancer (4.2%), four who had a second cancer and in whom the
cause of death could not be determined (1.9%), two who had a
non-adenocarcinoma colorectal cancer (0.9%) and 21 who died
from other causes (9.8%). A total of 178 cases remained available
for analysis (84% of potentially eligible cases). None of these
cases was known to have a previous history of colorectal cancer,
familial polyposis coli, ulcerative colitis or Crohn￿s disease before
colorectal cancer was diagnosed.
Identification of controls
For each case, four controls were randomly selected from the
enrolled population, and matched for sex, year of birth and place
of residence. Controls had to be alive when their matched case
died. In the event of death, the control was replaced. Each control
in the matched set thus had the same opportunity as the corre-
sponding case of undergoing a screening test. A previous history
of adenoma or non-fatal colorectal cancer first occurring after the
date of diagnosis of the corresponding case was not grounds for
exclusion.
Statistical analysis
The date of diagnosis of the case was applied to the case—control
matched set as the reference date, so as to ensure comparable inter-
vals for the screening history of cases and controls. The screening
history was taken from the time screening started to (and
including) the date of the case diagnosis, which was determined
from the screening campaign￿s data files. Eight or nine years of
data were available for all the case—control sets according to the
year of inclusion (1988 or 1989). In nine cases, it was specified
that the FOBT was used as a diagnostic test and not as a screening
test. These tests were not included in the analysis.
A conditional logistic regression for matched sets was used to
estimate the efficacy of FOBT screening in reducing mortality
from colorectal cancer. The ￿no screening￿ reference category
comprised subjects who had never participated at all. Efficacy is
suggested if a screening history is more common among controls
than cases. Separate ORs were also calculated by gender and
subsite (right colon, left colon and rectum). Interaction terms for
gender and subsite were tested for statistical significance. To
address the question of an optimal screening interval, ORs for
death from colorectal cancer were calculated for a history of faecal
occult blood screening at different time intervals before the refer-
ence date compared with ￿those never screened￿. Odds ratios for
death from colorectal cancer were also calculated by the number
of participations in the screening campaigns, ￿those never
screened￿ being the reference class. The 95% CIs are presented
for the estimated ORs. Analyses were carried out using EGRET
(1993, Statistics and Epidemiology Research Corporation,
Seattle, WA, USA).
RESULTS
In the four successive rounds of screening, compliance was 52.8%,
54.0%, 57.3% and 58.3%. Overall, 68.7% of the initially invited
population was given at least one screening test. Among the
persons enrolled in the fourth screening campaign, 50.8% partici-
pated in all four rounds.
A significantly smaller proportion of cases than of controls
underwent screening by FOBT during the study period. The OR of
subjects having been exposed to one or more FOBT during the
whole study period was 0.67 (95% CI 0.48—0.94) compared with
persons never screened. The negative overall association did not
differ significantly by gender (OR = 0.63%, 95% CI, 0.41—0.96,
for men; OR = 0.74, 95% CI 0.42—1.30, for women; P = 0.59) or
by cancer localization (P = 0.92). The magnitude of the mortality
reduction was slightly greater for left colon cancer (OR = 0.59,
95% CI 0.39—1.06) than for right colon cancer (OR = 0.76, 95%
CI, 0.39—1.51) or rectal cancer (OR = 0.71, 95% CI 0.41—1.21).
Table 1 shows the screening frequencies by the interval since
the most recent FOBT for cases and controls. A history of
Table 1 Odds ratio of death from colorectal cancer according to number of months since the most
recent screening FOBTa (conditional logistic regression model)
Time since last No. of subjects
screening FOBT screened (%)b
(years)
Cases Controls Matched ORc (95% CI) P
Never screened 86 (48.3) 277 (38.9) 1 < 0.001
1–3 months 26 (14.6) 53 (7.4) 2.02 (1.12–3.65)
4–12 months 29 (16.3) 154 (21.6) 0.58 (0.34–0.99)
13–24 months 25 (14.0) 173 (24.3) 0.40 (0.23–0.68)
25–36 months 3 (1.7) 30 (4.2) 0.32 (0.10–1.10)
37–48 months 3 (1.7) 11 (1.5) 0.84 (0.22–3.22)
49–60 months 1 (0.6) 7 (1.0) 0.41 (0.05–3.72)
> 60 months 5 (2.8) 7 (1.0) 2.09 (0.61–7.14)
aFOBT, faecal occult blood test. bNumber (and percentage) of subjects who had the most recent
screening test during each period of time. cFor each line we calculate the odds ratio of being exposed
to the most recent screening test during the specified period of time (compared with no FOBT).682 J Faivre et al
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screening with FOBT within 3 months of the reference date was
more common among cases than among controls. This finding was
reversed in the 4—12 to 25—36 month intervals, with controls more
likely to have been screened than cases. The OR increased towards
1 as the interval between the test and the diagnosis lengthened.
Consideration of screening intervals of 0—3 years and > 3 years
gave an OR for a screening FOBT of, respectively, 0.64 (95% CI
0.46—0.91) and 1.14 (95% CI 0.50—2.63).
We observed a negative association between the risk of death
from colorectal cancer and the number of screenings (P = 0.003,
Table 2). The risk decreased significantly for those who partici-
pated in two or more screening campaigns, compared with non-
participants (OR = 0.46, 95% CI 0.31—0.75). The mortality
reduction is estimated to be 70% among those who participated in
all four screening campaigns (OR = 0.30, 95% CI 0.12—0.76).
DISCUSSION
This case—control study suggests a 33% reduction in colorectal
cancer mortality for individuals screened by FOBT biennially. The
main advantages of this study are the opportunity of including all
deaths from colorectal cancer in a defined population and the
holding of information of similar quality on the history of partici-
pation in screening campaigns, for both cases and controls.
Matching of cases and controls by sex and birth year as well as
place of residence will have minimized the effect of sociodemo-
graphic and lifestyle risk factors that could have spuriously exag-
gerated the estimates of efficacy. Prior screening can be a
confounding factor in such studies but, before 1988, no cancer
screening programme existed in the study area and FOBT was not
available for individuals. Cases and controls were unlikely, there-
fore, to have been screened previously. Biases towards an apparent
benefit of screening might operate when individuals with a lower
risk of developing colorectal cancer are more likely to attend
screening. Through the population-based cancer registry, data are
available on the occurrence of colorectal cancer in non-partici-
pants of screening. Preliminary data indicate little difference in the
incidence of colorectal cancer between non-participants and the
control arm of the population studies. It is thus unlikely that selec-
tion bias of this type accounts for a substantial part of the reported
effect of screening. However, the difficulty of controlling for all
relevant confounding factors could still limit the accuracy of the
study.
Our findings are consistent with previous case—control studies
using the same FOBT, the Hemoccult test. Two case—control
studies conducted among members of health insurance plans on
the west coast of the United States and a population-based study in
the district of Florence, Italy, suggest a reduction in colorectal
cancer mortality of 28% (Lazovich et al, 1995), 25% (Selby et al,
1993) and 40% (Zappa et al, 1997) for people who performed a
Hemoccult test. In a German study, in which results were reported
by sex, mortality reduction was 57% for females and 8% for males
for those screened 6—36 months before the reference date
(Warhendorf et al, 1993). In one case—control study, no evidence
of efficacy was found (Newcomb et al, 1992). However, this 
study was very small, with only 66 cases, and the analysis was
conducted without regard to the period of screening. Compared
with the other studies, mortality reduction was higher in a
Japanese case—control study using an immunochemical haemag-
glutination test annually (Saito et al, 1995). This result is easily
explained by the higher sensitivity of this test. However, its speci-
ficity is not well established at a population level (probably lower
than the specificity of the Hemoccult test) and the test is more
expensive and more difficult to analyse and thus is not as suitable
for a mass screening programme.
The results of this case—control study also appear to be consis-
tent with true effectiveness, as reported by population-based
randomized trials (Hardcastle et al, 1996; Kronborg et al, 1996),
which found a colorectal cancer mortality reduction ranging
between 18% and 15%. As case—control studies compare partici-
pants with non-participants, they provide an indication of reduc-
tion in risk, that is independent of compliance rates. In randomized
studies, as in the general population, compliance rates affect the
final result. With a 50% compliance rate, true effectiveness in the
present study would be half of the mortality reduction reported.
None of the studies, except one, report a difference between
males and females for a protective effect of FOBT. The reason 
for the discrepancy seen in Saarland has not been explained
(Warhendorf et al, 1993). As found in the present study, it has been
previously reported that the protective effect of screening is of the
same order of magnitude whatever the anatomical location (Selby
et al, 1993; Saito et al, 1995). The slightly lower OR for sigmoid
and descending colon can be attributed to a higher sensitivity of
FOBT for these cancers (Thomas et al, 1992). It is much lower for
rectal cancers. Surprisingly, the Italian case—control study suggests
a higher reduction in risk for rectal cancer than for colon cancer
(Zappa et al, 1997). As expected we found that cases (persons with
fatal colorectal cancer) were more likely than controls to have
been screened in the 3 months before the reference date. It is easy
to understand that more cases than controls have undergone a
Table 2 Odds ratio of death from colorectal cancer according to number of participations before the reference date
(conditional logistic regression model)
No. of participations in No. of subjects (%)a
the screening campaigns
Cases Controls Matched OR (95% CI)b P
(n = 178) (n = 712)
Never screened 86 (48.3) 277 (38.9) 1 0.003
One 45 (25.3) 149 (20.9) 1.04 (0.67–1.58)
Two 21 (11.8) 126 (17.7) 0.50 (0.29–0.88)
Three 19 (10.7) 103 (14.5) 0.52 (0.28–0.94)
Four 7 (3.9) 57 (8.0) 0.30 (0.12–0.76)
aNumber (and percentage) of subjects who participated during each period. bOdds ratio and 95% CI to have a screening
history compared with no screening history before the reference date.Evaluation of colorectal cancer screening 683
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screening test in the short period preceding the diagnosis, thus
explaining this apparent risk increase. In the controls, who are
mostly without cancer, the screening tests are more scattered over
time. When considering the 4—12 month, 13—24 month and 25—36
month segments, a statistically significant protective effect was
seen. Similar findings have been observed in other studies.
Wahrendorf et al (1993) considered mainly the time period 6—36
months prior to diagnosis and the effect of screening was consid-
erably lower when the first 6-month period was included.
Lazovich et al (1996) found no protective effect when considering
the whole year before the reference date. The authors have shown
that this result cannot be explained by the use of FOBT as a diag-
nostic test. Risk estimates were unchanged when the analysis was
restricted to those FOBT declared to be performed in asympto-
matic subjects.
As in other studies, our data indicate that the risk was lower for
a 3-year period and that no reduction in risk existed when consid-
ering longer periods. Such findings lie behind current screening
recommendations suggesting that FOBT should be repeated at
least biennially. The risk estimate of dying of colorectal cancer
associated with the number of participations in screening
campaigns was decreased significantly only in those who partici-
pated in two or more screening campaigns. No mortality reduction
was shown in those who participated only once, thus suggesting
that a possible selective effect of participants cannot be held as an
explanation for the observed mortality reduction.
We conclude that this population-based case—control study
contributes further evidence that biennial faecal occult blood
screening with the Hemoccult II test can reduce colorectal cancer
mortality. However, because the case—control method takes no
account of participation rates, allowance must be made for this
factor in interpreting the results.
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